SAFETY DATA SHEET



1. Identification

Product identifier TELAZOL

Other means of identification

Synonyms TELAZOL® * Tiletamine HCL and Zolazepam HCL

Recommended use Veterinary anesthetic agent

Recommended restrictions Not for human use

Manufacturer/Importer/Supplier/Distributor information

Company Name (USA) Zoetis Inc.

10 Sylvan Way

Parsippany, New Jersey 07054 (USA)

Rocky Mountain Poison

and Drug Center

1-866-531-8896

Product Support/Technical

Services

1-800-366-5288

Emergency telephone

numbers

CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Company Name (CA) Zoetis Canada Inc.

16740 Trans-Canada Highway Kirkland, Quebec, H9H 4M7

Emergency telephone

number

International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail productsupport@zoetis.com

Product Support 1-800-461-0917

All Safety Data Sheets are available via our Zoetis Canada website at

https://www.zoetis.ca/sds/sds.aspx

Supplier Not available.

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Reproductive toxicity (the unborn child) Category 2

Specific target organ toxicity following single

exposure

g single Category 3 narcotic effects

Specific target organ toxicity following

repeated exposure

Category 2 (central nervous system, kidney,

pancreas)

Environmental hazards Not classified.

Label elements



Signal word Warning

Hazard statementMay cause drowsiness or dizziness. Suspected of damaging the unborn child. May cause damage to organs (central nervous system, kidney, pancreas) through prolonged or repeated exposure.

Precautionary statement

Prevention

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe mist or vapour. Use only outdoors or in a well-ventilated area.

Wear protective gloves/protective clothing/eye protection/face protection.

IF exposed or concerned: Get medical advice/attention. IF INHALED: Remove person to fresh air Response

and keep comfortable for breathing. Call a POISON CENTRE/doctor if you feel unwell.

Store in a well-ventilated place. Keep container tightly closed. Store locked up. Storage

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Other hazards None known.

Supplemental information Anesthetic drug: may cause central nervous system and cardiovascular system effects. May

cause eye and skin irritation. May cause irritation of respiratory tract. Individuals sensitive to this

material or other materials in its chemical class may develop allergic reactions.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Mannitol		69-65-8	<6
Tiletamine hydrochloride		14176-50-2	50 mg/ml
Water for Injection		7732-18-5	
Zolazepam hydrochloride		33754-49-3	50 mg/ml

All concentrations are in percent by weight unless ingredient is a gas. Gas concentrations are in percent by volume.

4. First-aid measures

Remove victim to fresh air and keep at rest in a position comfortable for breathing. If breathing is Inhalation

difficult, trained personnel should give oxygen. Get medical attention immediately.

Wash off with soap and plenty of water. Remove contaminated clothing. If skin irritation or rash Skin contact

occurs: Get medical advice/attention. Wash contaminated clothing before reuse.

Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses. Eye contact

Continue rinsing. Call a physician or poison control centre immediately.

Rinse mouth. Call a physician or poison control centre immediately. Do not induce vomiting without Ingestion

advice from poison control center. Never give anything by mouth to a victim who is unconscious or

is having convulsions.

Most important

symptoms/effects, acute and

delayed

May cause drowsiness and dizziness. Narcosis. Headache. Nausea, vomiting. Behavioural changes. Decrease in motor functions. Prolonged exposure may cause chronic effects. Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused respiratory depression, gastrointestinal disturbances, allergic skin rash. Anesthetic drug: may cause central nervous system and cardiovascular system effects

Indication of immediate medical attention and special treatment needed

General information

Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed. Anesthetic drug: may cause central nervous system and cardiovascular system effects Monitor respiratory, cardiac and central nervous system.

IF exposed or concerned: Get medical advice/attention. For personal protection, see section 8 of the SDS. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance.

5. Fire-fighting measures

Suitable extinguishing media Unsuitable extinguishing

media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Move containers from fire area if you can do so without risk.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials. General fire hazards No unusual fire or explosion hazards noted.

Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. Ensure adequate ventilation. Do not breathe mist or vapour. Avoid contact with eyes, skin, and clothing. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. For personal protection, see section 8 of the SDS. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up Ensure adequate ventilation. Avoid release to the environment. Prevent entry into waterways, sewer, basements or confined areas. Remove sources of ignition.

Large Spills: Stop the flow of material, if this is without risk. Cover with plastic sheet to prevent spreading. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS.

Environmental precautions

Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Wear appropriate personal protective equipment. Provide adequate ventilation. Avoid breathing mist or vapour. Avoid contact with eyes, skin, and clothing. Avoid accidental injection. Avoid prolonged exposure. Wash thoroughly after handling. When using, do not eat, drink or smoke. Avoid release to the environment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities Store locked up. Store in a well-ventilated place. @ 15-30°C (59-86°F). Protect from sunlight. Use care in handling/storage. Store away from incompatible materials (see Section 10 of the SDS). Keep out of the reach of children.

8. Exposure controls/personal protection

Occupational exposure limits

No exposure limits noted for ingredient(s).

Biological limit values

Control banding approach

No biological exposure limits noted for the ingredient(s). Tiletamine hydrochloride: Zoetis OEB 2 (control exposure to the range of 100ug/m3 to <

1000ug/m3)

Zolazepam hydrochloride: Zoetis OEB 3 (control exposure to the range of 10ug/m3 to < 100ug/m3)

Appropriate engineering controls

Ensure adequate ventilation, especially in confined areas. Keep air contamination levels below the exposure limits or within the OEB range listed above in this section. General ventilation normally adequate.

Wear protective gloves. Impervious gloves are recommended if skin contact with drug product is

Individual protection measures, such as personal protective equipment

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection

possible and for bulk processing operations.

Other Wear suitable protective clothing. Use protective clothing (uniforms, lab coats, disposable

coveralls, etc.) in both production and laboratory areas.

Respiratory protection No personal respiratory protective equipment normally required. In case of insufficient ventilation,

wear suitable respiratory equipment. If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range. Respiratory protection should be provided in instances where exposure to dust, mists, aerosols or vapors are likely. Chemical respirator with

organic vapour cartridge, full facepiece, dust and mist filter.

Not applicable. Thermal hazards

General hygiene considerations

Observe any medical surveillance requirements. Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

Physical and chemical properties

Appearance Liquid. (After reconstitution).

Physical state Liquid. Liquid. Form Off-white. Colour Not available. Odour Not available. Odour threshold

3.5

Melting point/freezing point Not available.

Initial boiling point and boiling 100 °C (212 °F)

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not applicable.

Upper/lower flammability or explosive limits

Flammability limit - lower Not

(%)

Not available.

Flammability limit - upper

/0/\

Not available.

Explosive limit - lower (%)
Explosive limit - upper

Not available. Not available.

(%)

Vapour pressureNot available.Vapour densityNot available.Relative densityNot available.

Solubility(ies)

Solubility (water) Slightly soluble

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

Other information

Explosive properties Not explosive.

Oxidising properties Not oxidising.

Specific gravity 1.52 (Mannitol)

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoidContact with incompatible materials.

Incompatible materials Strong oxidising agents.

Hazardous decomposition Irritating and/or toxic

products

Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition. May

include products of carbon, nitrogen. May include hydrogen chloride.

11. Toxicological information

Information on likely routes of exposure

Inhalation May cause drowsiness and dizziness. Headache. Nausea, vomiting. May cause irritation to the

respiratory system.

Skin contact Prolonged skin contact may cause temporary irritation. **Eye contact** Direct contact with eyes may cause temporary irritation.

Ingestion May be harmful if swallowed. However, ingestion is not likely to be a primary route of occupational

exposure.

Symptoms related to the physical, chemical and toxicological characteristics

May cause drowsiness and dizziness. Narcosis. Headache. Nausea, vomiting. Behavioural changes. Decrease in motor functions. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused respiratory depression, gastrointestinal disturbances, allergic skin rash. Anesthetic drug: may cause central nervous system and cardiovascular system effects

Information on toxicological effects

Acute toxicity May be harmful if inhaled. May be harmful if swallowed.

Product **Species** Test results **TELAZOL** Acute Oral LD50 Rat > 5000 mg/kg (ATE) Components Species Test results Mannitol (CAS 69-65-8) Acute Oral LD50 Mouse 22 g/kg Rat 13500 mg/kg Zolazepam (CAS 31352-82-6) **Acute** Oral LD50 Rat 398 ma/ka Subchronic LOAEL Dog 10 mg/kg/day, 3 months [Target organ(s): Central Nervous System, Gastrointestinal systeml 10 mg/kg/day, 3 months [Target organ(s): Monkey Central Nervous System] NOAEL Rat 10 mg/kg/day, 91 days [Target organ(s): Pancreas, Kidney] Prolonged skin contact may cause temporary irritation. Skin corrosion/irritation Serious eye damage/eye Direct contact with eyes may cause temporary irritation. irritation Respiratory or skin sensitisation Respiratory sensitisation Not a respiratory sensitizer. Skin sensitisation Due to partial or complete lack of data the classification is not possible. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. No data available to indicate product or any components present at greater than 0.1% are Germ cell mutagenicity mutagenic or genotoxic. Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. Reproductive toxicity Suspected of damaging the unborn child. This compound can cross the placenta in pregnant Specific target organ toxicity -May cause drowsiness and dizziness. single exposure May cause damage to organs (central nervous system, kidney, pancreas) through prolonged or Specific target organ toxicity repeated exposure repeated exposure. Not an aspiration hazard. **Aspiration hazard** Chronic effects May cause damage to organs through prolonged or repeated exposure. Anesthetic drug: may cause central nervous system and cardiovascular system effects. **Further information** Accidental injection of this product may result in anesthetic and other central nervous system effects. Convulsions, lethargy, respiratory depression, and muscle relaxation may occur. Cardiovascular effects (increase heart rate, changes in blood pressure) may also occur. Pulmonary edema with resultant shortness of breath may be seen as well as nausea and vomiting. 12. Ecological information The product is not classified as environmentally hazardous. However, this does not exclude the **Ecotoxicity** possibility that large or frequent spills can have a harmful or damaging effect on the environment.

possibility that large of frequent spills can have a narmul of damaging effect on the environment.

Avoid release to the environment.

Persistence and degradability No data is available on the degradability of this product.

Bioaccumulative potential No data available.

Mobility in soil No data available.

Other adverse effects

No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructions

Avoid release to the environment. Do not discharge into drains, water courses or onto the ground. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container in accordance with local/regional/national/international regulations.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

None known.

Waste from residues / unused products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).

Contaminated packaging

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

TDG

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and

Not established.

the IBC Code

15. Regulatory information

Canadian regulations

This product has been classified in accordance with the hazard criteria of the HPR and the SDS contains all the information required by the HPR.

Controlled Drugs and Substances Act

Not regulated.

Export Control List (CEPA 1999, Schedule 3)

Not listed.

Greenhouse Gases

Not listed.

Precursor Control Regulations

Not regulated.

International regulations

Stockholm Convention

Not applicable.

Rotterdam Convention

Not applicable.

Kyoto protocol

Not applicable.

Montreal Protocol

Not applicable.

Basel Convention

Not applicable.

International Inventories

Country(s) or regionInventory nameOn inventory (yes/no)*AustraliaAustralian Inventory of Chemical Substances (AICS)NoCanadaDomestic Substances List (DSL)No

China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances	No

(PICCS)

Inventory name

United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory

Non-Domestic Substances List (NDSL)

16. Other information

Country(s) or region

Canada

Issue date 28-April-2017

Version No. 01

List of abbreviations ATE: Acute Toxicity Estimate according to REGULATION (EC) No 1272/2008 (CLP).

Disclaimer Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while

it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently

available.

Revision information Product and Company Identification: Physical States

Composition / Information on Ingredients: Ingredients Physical & Chemical Properties: Multiple Properties Toxicological Information: Toxicological Data

GHS: Qualifiers

Material name: TELAZOL SDS CANADA

On inventory (yes/no)*

No

No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).